Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Atezolizumab, pertuzumab and trastuzumab with chemotherapy as neoadjuvant treatment for HER2-positive high-risk early or locally advanced breast cancer
2017-000981-31Phase 3Active
- Sponsor
- Michelangelo Foundation
- Start
- Aug 2018
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Cytotoxic ADCs → Antibody-Drug Conjugates (ADCs) → Antibody Conjugates → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 3, randomised trial of atezolizumab, pertuzumab, trastuzumab and trastuzumab emtansine in breast cancer (3 arms), sponsored by Michelangelo Foundation. Primary endpoint: 5-year event-free survival. Started Aug 2018; status: active.
02
Drugs
03
Conditions
breast cancer
Beyond the preview
Go deeper on 2017-000981-31.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2017-000981-31.